Zydus Lifesciences inches up as its arm incorporates wholly owned subsidiary in USA
Zydus Lifesciences is currently trading at Rs. 980.35, up by 0.75 points or 0.08% from its previous closing of Rs. 979.60 on the BSE.
The scrip opened at Rs. 981.60 and has touched a high and low of Rs. 990.35 and Rs. 972.00 respectively. So far 101066 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 797.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 1003.80 and Rs. 963.45 respectively. The current market cap of the company is Rs. 98615.96 crore.
The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 18.33% and 6.68% respectively.
Zydus Lifesciences’ wholly owned subsidiary -- Zydus Pharmaceuticals USA Inc., USA, (ZPUI) has incorporated a wholly owned subsidiary in the name of a Zylidac Bio LLC (Zylidac) in the United States of America on July 11, 2025, and is yet to commence its business operation. The immediate objective of incorporation of Zylidac is to acquire the target assets of Agenus.
Earlier, ZPUI has entered into a definitive agreement with Zylidac, and Agenus Inc., USA (collectively referred to as ‘Agenus’), to acquire, directly or through its affiliates, two U.S. based biologics manufacturing facilities of Agenus, one in Emeryville, CA and another in Berkeley, CA (‘the target assets’).
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
